Beclometasone

Quick links to important sections

Beclometasone

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beclometasone

Quick Facts

Property Description
Active ingredient Beclometasone dipropionate (INN)
Form Inhaler, Nasal spray, Topical cream, Oral tablet
Pharmacological class Corticosteroid, Glucocorticoid
Common purpose Reducing chronic local swelling and irritation
Origin Synthetic (Glucocorticoid ester)

What Type of Medicine is Beclometasone?

Beclometasone is a synthetic corticosteroid medicine that belongs to the Glucocorticoid class of steroid hormones. Specifically, the active compound is Beclometasone dipropionate (INN), which is classified as a glucocorticoid ester designed for potent, targeted action. The drug’s fundamental purpose is to function as a powerful anti-inflammatory agent and localized immunosuppressant. As a steroid, Beclometasone works to relieve inflammation and has been clinically recognized for decades as a crucial long-term management tool for inflammatory conditions.


Composition and Available Forms

The medication's active ingredient is Beclometasone dipropionate, which is formulated with specialized vehicles to enable precise delivery. Beclometasone is commonly available in several dosage forms, including the metered-dose inhaler (MDI) or powder inhaler (DPI), nasal spray, and topical cream. These forms dictate the route of administration, which is most often inhalation, intranasal, or topical (dermal). The primary use of Beclometasone is to reduce inflammation. The unique advantage of its inhaled and intranasal forms, frequently marketed under brands like Qvar, is the high concentration of the glucocorticoid delivered to the respiratory or nasal mucosa. Crucially, most preparations are engineered for local administration, confining the high anti-inflammatory potency to the specific site of application, such as the airways or skin, rather than eliciting a systemic (whole-body) effect.


What Is the General Benefit of a Glucocorticoid Ester?

The general benefit of this type of glucocorticoid ester is its ability to reduce chronic swelling and irritation by consistently suppressing the underlying inflammatory and immune responses. Beclometasone achieves this by altering the release of inflammatory chemicals and inhibiting the activity of immune cells at the site of application. This targeted suppression breaks the cycle of chronic irritation, which serves as the core mechanism by which the medication helps relieve congestion, tightness, and persistent discomfort associated with inflammatory conditions.

Regulatory References

  1. Beclomethasone (Oral Inhalation) Information
  2. Trydonis EPAR Summary

What side effects are possible with Beclometasone?

Possible Side Effects and Safety Information

The safety profile of Beclometasone dipropionate is formally documented by regulatory authorities, classifying possible adverse reactions by frequency and affected organ system.


Official Adverse Reaction Classifications

Adverse reactions are grouped according to the physiological system involved and their reported frequency, as detailed in official government labeling:

Classification Examples of Reactions
Very Common Candidiasis of the mouth and throat (thrush), Headache (inhaled form).
Common Hoarseness, cough, throat irritation, rhinitis.
Uncommon Hypersensitivity reactions (e.g., rash, urticaria).
Very Rare Paradoxical bronchospasm, Adrenal suppression, Glaucoma, Cataract, Angioedema.

Major System-Organ Classes involved include Infections and Infestations, Immune System Disorders, Endocrine Disorders, Psychiatric Disorders, and Eye Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions, which are rare but clinically significant. These include paradoxical bronchospasm—an immediate, severe worsening of breathing—and systemic effects such as adrenal suppression and the development of cataract or glaucoma, which are typically associated with prolonged high-dose use.

Safety notes also address specific populations and usage patterns:

  • Pediatric Safety: The risk of growth retardation is a documented systemic effect, leading to the regulatory recommendation for monitoring the height of children and adolescents on prolonged therapy.
  • Duration-Related Patterns: Systemic adverse effects are generally associated with long-term use at high doses.
  • Restrictions: Beclometasone is not indicated for the relief of acute bronchospasm (as a rescue medicine) or the primary treatment of status asthmaticus. Use is contraindicated in individuals with known hypersensitivity.

Overdose and Emergency Response

Overdose: What to Know

Overdose with beclometasone is primarily associated with the risk of systemic corticosteroid effects, generally following prolonged use or exposure to doses higher than those recommended by a healthcare provider. Acute, single-instance overdose (such as swallowing a large amount) is typically associated with low toxicity and is not expected to cause immediate, life-threatening symptoms.

When to Seek Immediate Medical Help

If you suspect an overdose, or if an accidental ingestion of a large amount has occurred, contact emergency medical services or a poison control center immediately. Provide the name of the product, the amount taken, and the time the exposure occurred.

Symptoms of Concern from Excessive Exposure

While an acute event is low-risk, chronic use of excessively high doses can lead to signs of hypercorticism, which are systemic effects of the medication on the body. These may include the potential for adrenal suppression (a weak adrenal gland) or, in rare cases, Cushingoid features.

Symptoms that may indicate a need for urgent medical attention include:

  • Signs of a serious allergic reaction, such as swelling of the face, throat, or tongue, or severe difficulty breathing.
  • Worsening or new breathing problems (paradoxical bronchospasm) immediately following use of the inhaler.
  • Symptoms of adrenal insufficiency, such as severe tiredness, muscle weakness, confusion, or severe gastrointestinal upset.

If any of these serious manifestations occur, seek urgent medical help immediately.

Therapeutic Uses of Beclometasone

What Beclometasone Treats: Main Uses and Benefits

This medication is used across multiple therapeutic domains primarily to assist with symptoms related to inflammatory or irritative states. It provides supportive relief when symptoms intensify or interfere with daily functioning.


Easing Symptoms of Respiratory Discomfort

Beclometasone is commonly used to help manage symptoms linked to organ-specific functional stress, such as in asthma and certain symptoms associated with COPD. It supports patients during episodes of heightened discomfort by addressing symptoms related to heightened physiological activity like wheezing or chest tightness. This agent is commonly used to help manage symptoms linked to condition categories such as asthma, allergic rhinitis (hay fever), and corticosteroid-responsive dermatoses.


Providing Relief from Nasal Congestion and Inflammation

This agent is applied when supportive symptom management is appropriate for conditions like allergic rhinitis. It is relevant for easing symptoms that may interfere with daily functioning, such as a runny or blocked nose and sneezing, which can create noticeable physiological strain. It is also applied in settings where symptoms are linked to recurrent nasal polyps.

Quick Fact: Supportive Care for Symptom Management
Beclometasone supports patients during difficult episodes by helping to ease symptoms associated with acute or episodic changes and supporting day-to-day comfort.

Supporting Management of Acute Inflammatory Episodes

Beclometasone is used in situations involving certain distressing symptoms, including those associated with corticosteroid-responsive dermatoses (creams/ointments). This application is relevant in contexts marked by increased discomfort or tension, providing symptomatic support for conditions that present with systemic or localized discomfort.

Eligibility and Restrictions for Use

Who can and cannot use Beclometasone?

Eligibility to use Beclometasone is strictly defined by regulatory documents based on age, hypersensitivity, and pre-existing clinical conditions. This medicine is primarily intended for maintenance treatment and is not approved for use in all populations.


Contraindications and Restrictions

Classification Official Regulatory Status
Absolute Contraindication Patients with known hypersensitivity to the active ingredient or any excipient; use for the primary treatment of acute status asthmaticus or severe acute asthma.
Age-Related Eligibility Safety and efficacy are not established in children younger than 4 years of age for most forms. Approved for children typically mathbf4 to 5 years and older.
Conditional Use Use requires caution in patients with active or quiescent tuberculosis, ocular herpes simplex infection, or other untreated systemic infections (fungal, bacterial, viral).
Organ Impairment Use with caution in patients with severe hepatic or severe renal impairment, considered only if the potential benefit outweighs the documented risk due to insufficient data.
Pregnancy/Lactation Use only when the potential benefit justifies the potential risk to the fetus or child, as noted in official prescribing information.

The official eligibility profile limits use to approved age groups and strictly prohibits use during acute life-threatening respiratory events. Conditional use is imposed on populations with certain pre-existing infections or organ limitations, requiring adherence to the restrictions defined in governmental labeling.

What should I know about interactions with other medicines?

The official interaction profile for Beclometasone is established through regulatory documents, defining constraints based on pharmacokinetic (PK) and pharmacodynamic (PD) risks. The core interaction pattern is a risk of either heightened systemic drug exposure or additive pharmacological effects.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Categories/Substances Regulatory Outcome
Pharmacokinetic (PK) Strong CYP3A4 Inhibitors (e.g., Ritonavir, Cobicistat) Increased systemic exposure
ightarrow Risk of systemic corticosteroid effects, including adrenal suppression.
Pharmacodynamic (PD) Other Corticosteroids (oral, topical, inhaled) Additive glucocorticoid effect
ightarrow Increased risk of systemic side effects.

Co-administration with strong CYP3A4 inhibitors is restricted or requires monitoring due to the potential for reduced clearance of the active metabolite and subsequent systemic accumulation. The major pharmacodynamic restriction involves the risk of additive effects from concurrent glucocorticoid activity.

Specific Interaction Notes

A formulation-specific interaction is documented regarding the ethanol excipient present in some inhaler products, which may interact with medicines such as Disulfiram or Metronidazole. Furthermore, official labels note that patients with Hepatic Impairment should be closely monitored for signs of increased systemic drug exposure due to potential alterations in drug clearance.

Mechanism of Action

Mechanism of Action: Beclometasone

Beclometasone is an agonist that easily crosses the cell membrane to bind to the cytoplasmic Glucocorticoid Receptor (GR). This interaction activates the drug-receptor complex, which then translocates into the cell nucleus. The complex primarily acts via transrepression, directly interacting with and inhibiting pro-inflammatory transcription factors, such as NF-κB and AP-1, thereby limiting the transcription of target inflammatory genes.

This molecular cascade decreases the synthesis of inflammatory proteins, including cytokines and chemokines, and reduces the activation of local immune cells in the airways. The resulting downstream physiological effects include a decrease in local vascular permeability and a reduction in mucus secretion, influencing tissue parameters in the respiratory system.

Dosage and Administration Information

How Beclometasone is Used: Administration Guidelines

The usage of beclometasone dipropionate is defined by the route of administration, which aligns with its local action. The primary routes are Inhalation (for respiratory maintenance), Intranasal (for nasal conditions), and Topical (for dermal use). This medication is intended for long-term daily maintenance when inhaled or intranasally administered, contrasting with the short-term courses typical for topical application.

Dosing and Frequency Patterns

Dosing regimens are established to achieve control and then transition to the lowest effective dose. For adult Inhalation, initial and maintenance doses commonly range from 100 µg to 1000 µg total daily, which may be administered once or as a divided dose (twice daily). Intranasal administration often starts at 50 µg or 100 µg per nostril, typically taken twice daily. Pediatric patients require specific, lower starting doses and lower maximum daily limits than those prescribed for adults.

Key Procedural Instructions

Entity Procedural Instruction
Administration Timing The inhaled form is for maintenance use and is taken regularly, not for acute symptoms.
Missed Dose If a dose is missed, the next scheduled dose is taken at the usual time; the dose is not doubled to compensate.
Preparation Nasal spray devices are primed by actuating the spray until a fine mist appears before initial use.
Post-Use Requirement After administering the inhaled form, the standard procedure is to rinse the mouth with water and spit the water out.

This structured approach ensures the medication is used consistently and technically correctly, establishing the protocol for proper administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Beclometasone

Evidence for Use in Chronic Asthma (Inhaled Form)

The research foundation includes a large body of evidence from Randomized Controlled Trials (RCTs) and systematic reviews. These studies explored outcomes related to functional imbalance linked to chronic asthma, covering adults, adolescents, and children from two years of age. Researchers examined various objective measures of pulmonary function, such as FEV1 and PEF, alongside clinical parameters like the frequency of asthma exacerbations (relapses). Findings contribute to the broader evidence landscape on symptom changes.

Evidence for Use in Allergic Rhinitis (Nasal Spray)

The use of the nasal spray formulation was evaluated in short-term, placebo-controlled, double-blind RCTs. This research primarily involved patients with conditions associated with acute or disruptive episodes like seasonal and perennial allergic rhinitis. Studies explored changes in subjective nasal symptom scores (e.g., TNSS) and monitored outcomes reflecting daily functioning. Findings help contextualize how patients reported their experience related to physical discomfort over periods of short-term study.

Long-Term Data, Specific Groups, and Research Gaps

Research has monitored patients over defined time intervals. For chronic asthma, many key trials extended follow-up durations to between six months and over one year, examining long-term patterns related to changes in lung function. Studies was evaluated in specific patient groups, including children and those dependent on oral steroids. Research examined the effects of increasing the dose above a specific threshold, but evidence is limited in this area for mild-to-moderate disease. Furthermore, data for certain groups remain insufficient, particularly for patients with the most severe forms of asthma. Long-term effects are not fully established beyond documented observation periods.

Frequently Asked Questions (FAQ)

Common questions about Beclometasone (FAQ)


Q: How quickly does Beclometasone usually start to work?

A: Regulatory documents indicate that for formulations such as the nasal spray, initial significant relief may begin within 3 days of starting regular use. However, official product information clarifies that it can take up to two weeks of consistent use to achieve the maximum level of symptomatic relief.


Q: What's the difference between Beclometasone and Fluticasone?

A: According to official sources, Beclometasone and Fluticasone are both categorized in the same drug class as glucocorticoids or steroids. This means they share the same general purpose of reducing local swelling and irritation. While they have similar effects, each has its own unique chemical structure and specific regulatory information regarding its approved uses.


Q: Can Beclometasone be used long-term?

A: Yes, Beclometasone is often intended for long-term daily maintenance use for chronic conditions. However, official safety information associated with all corticosteroids notes that systemic effects, such as a risk of adrenal suppression or the development of conditions like cataracts or glaucoma, are typically associated with prolonged high-dose exposure.


Q: Does Beclometasone affect mood or anxiety levels?

A: Official product information notes that some psychological or behavioral effects may occur as a possible, though generally rare, adverse reaction. These reported effects can include changes such as anxiety, depression, or aggression. Regulatory documents recommend that patients inform their prescribing professional about all concerning changes or symptoms.


Q: What is the difference between Beclometasone and Montelukast?

A: Official sources categorize these medicines into different pharmacological classes. Beclometasone is a corticosteroid/glucocorticoid, working directly to suppress local inflammation. In contrast, Montelukast is classified as a leukotriene receptor antagonist, which blocks the action of inflammatory chemicals called leukotrienes. They target inflammation through different regulatory pathways.


Q: Can Beclometasone affect my sleep?

A: Regulatory documents indicate that, in rare instances, a range of psychiatric disorders have been reported as adverse reactions. These reports include instances of sleep disorders or insomnia, particularly when the medicine is used by children. Sleep-related effects are not listed as a common occurrence.


Q: Is Beclometasone safe to use during pregnancy?

A: Official prescribing information states that the use of Beclometasone during pregnancy is conditional. It is to be used only if the potential benefit justifies the potential risk to the fetus. Regulatory documents advise that infants born to mothers who used corticosteroids during pregnancy should be monitored for hypoadrenalism (low cortisol production).


Q: Can Beclometasone be used while breastfeeding?

A: Official labeling notes that it is unknown if the drug is excreted into human milk. Therefore, use of Beclometasone while breastfeeding requires a careful consideration of the potential benefits for the patient versus the potential risks to the breastfed child.


Q: Does Beclometasone interact with pain relievers like ibuprofen?

A: While formal interaction studies with all non-steroidal anti-inflammatory drugs (NSAIDs) are not typically conducted, official documentation sometimes reports that no clinically important differences were noted when this type of pain reliever was used at the same time as Beclometasone during clinical trials.


Q: Does Beclometasone interact with herbal supplements?

A: Official drug labels generally do not contain specific data or testing on herbal remedies or supplements. Official documentation notes the importance of informing the prescribing professional about all concomitant medicines, including any herbal remedies or supplements.


Q: Why do doctors prescribe Beclometasone instead of other steroids sometimes?

A: Regulatory documents confirm that Beclometasone is specifically formulated for local administration, such as through inhalation or as a nasal spray. This method of delivery is intended to concentrate the anti-inflammatory action at the specific site of application, like the airways or nasal passages, with the intention of limiting the drug's systemic exposure.


Q: Is it true that Beclometasone can affect bone density?

A: Official prescribing information includes a warning that decreases in bone mineral density may occur with the long-term use of corticosteroids. Monitoring is generally recommended for patients with pre-existing risk factors that may predispose them to decreased bone mineral content.


Q: Does Beclometasone make you drowsy?

A: Drowsiness or sedation is not typically listed as a common adverse reaction in official product information. The most commonly reported neurological side effect is a headache.


Q: Are there any specific lifestyle changes recommended when using Beclometasone?

A: Official patient instructions define specific post-administration procedures for some forms of the medicine. For the inhaled form, for example, users are specifically instructed to rinsing the mouth with water and spit afterwards to reduce the risk of local adverse effects.


Q: How long does the effect of a single use of Beclometasone last?

A: Regulatory documents include pharmacokinetic data that describes how the body handles the medicine. This information indicates that the active metabolite of Beclometasone is cleared from the systemic circulation with a terminal elimination half-life of approximately 2.7 hours.


Q: Can Beclometasone affect blood sugar levels?

A: According to official warnings and precautions, corticosteroids like Beclometasone may lead to conditions like hyperglycemia (high blood sugar) in rare instances. Patients using the drug, especially those with pre-existing conditions that affect blood sugar, may require monitoring.


Q: Are there any common interactions with foods or beverages?

A: Regulatory documents note a formulation-specific interaction involving the ethanol (alcohol) excipient present in some inhaler products. This excipient may interact with certain specific medications, such as disulfiram or metronidazole.


Q: Does Beclometasone interact with birth control pills?

A: Official drug interaction lists sometimes include hormonal contraceptives, such as those containing ethinyl estradiol, as medicines that may affect the concentration of the steroid in the body. Caution or dose adjustment may be required when these are used together.


Q: Is it okay to use alcohol while using Beclometasone?

A: Official labeling contains warnings only about the ethanol excipient in some formulations and its interaction with specific medicines. General consumption of alcoholic beverages is not typically addressed, but regulatory documents recommend that patients inform their prescribing professional about all concomitant substances.


Q: What should I do if I accidentally use too much Beclometasone?

A: Official overdose information states that the only potentially harmful effect following inhalation of a very large amount over a short period is temporary suppression of hypothalamic-pituitary adrenal (HPA) axis function. For acute overdose, regulatory text notes that no special emergency action is typically required.


Q: How is the safety of Beclometasone monitored after it's been approved?

A: The safety of Beclometasone is continuously monitored by regulatory agencies after its approval. This is achieved through mandatory adverse event reporting and by reviewing data collected from Post-Marketing Experience, which is compiled and included in updated drug labels.


Q: Can Beclometasone be used at the same time as an antibiotic?

A: Official warnings state that caution is often required when using corticosteroids in patients with untreated systemic infections (fungal, bacterial, or viral). This is often due to the potential for immunosuppressive effects associated with corticosteroids. Specific interactions with most antibiotics are not usually listed, but the presence of an infection is a key factor.


Q: Is it okay to stop using Beclometasone suddenly?

A: Regulatory documents state that if conditions such as Hypercorticism and Adrenal Suppression occur due to use, the medicine should be discontinued slowly. An abrupt withdrawal from regular use may lead to signs and symptoms of steroid withdrawal.


Q: What does 'systemic absorption' mean in relation to Beclometasone?

A: Systemic absorption refers to the amount of medicine, or its active ingredients, that enters the general bloodstream from the site of application (such as the lungs or nose). Regulatory texts provide data to quantify how much of the drug is systemically absorbed after use.


Q: Are there any known interactions between Beclometasone and vaccines?

A: Official drug interaction lists sometimes mention specific vaccines in the context of required caution or monitoring when used concomitantly with corticosteroids. This is due to the potential for immunosuppressive effects, which may affect the body's response to the vaccine.


Q: Is Beclometasone related to other 'sone' medicines?

A: Beclometasone is classified as a glucocorticoid or steroid. This pharmacological class includes many other similar drugs, which often share the '-sone' or '-solone' suffix. This common suffix is a chemical indicator of their shared physiological activity as corticosteroids.

How should Beclometasone be stored and disposed of?

How to Store and Dispose of Beclometasone

Beclometasone must be stored strictly according to governmental regulatory requirements to maintain its stability and effectiveness.


Labeled Storage Conditions

Requirement Specification
Temperature Range Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Prohibited Environments Must be protected from freezing and must not be stored or used near heat or an open flame.
Canister Safety Pressurized aerosols must not be punctured or incinerated due to contents being under pressure.
Child Safety Must be stored out of the sight and reach of children.

Discard and Stability Rules

All products must be discarded after the expiration date. Inhalers must be discarded when the dose counter reads 0, and nasal sprays must be discarded after a specified number of sprays, such as 180 actuations. Unused or expired Beclometasone must be disposed of according to the labeled product instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beclometasone found in:

A-Z Index: